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Evaluation of the genotype MTBDRplus assay for the
diagnosis of tuberculosis and rapid detection of rifampin and
isoniazid resistance in clinical specimens*
Cengiz ÇAVUŞOĞLU, Derya GÜRSEL, Hale BOZKURT AKTOPRAK
Aim: To determine the performance of the Genotype MTBDRplus assay for diagnosis of tuberculosis and rapid detection
of rifampin (RIF) and isoniazid (INH) resistance in clinical specimens.
Materials and methods: A total of 90 clinical specimens of 57 patients (69 sputum samples, 11 bronchoscopic aspirates,
5 bronchoalveolar lavage, 4 deep tracheal aspirate, 1 lymph aspirate) sent to the Ege University Medical Faculty,
Department of Medical Microbiology, Mycobacteriology Laboratory between December 2007 and 2009 during the
clinical routine were included in the study.
Results: Overall 80 valid results were obtained for 90 clinical specimens (88.9%) with MTBDRplus. While 74 of 82
(90.2%) smear positive specimens gave interpretable results by MTDRplus, 2 of 8 smear negative specimens gave invalid
results. The overall rates of concordance between the results of the MTBDRplus assay and those of the drug susceptibility
testing for the assessment of RIF and INH resistance were 97.5% (78/80) and 98.8% (79/80), respectively.
Conclusion: Although the MTBDRplus assay could be a useful tool for rapid identification of RIF- and INH-resistant
Mycobacterium tuberculosis in both clinical samples and strains, the test results must always be confirmed by culture
and drug susceptibility testing.
Key words: Mycobacterium tuberculosis, rifampin resistance, isoniazid resistance, Genotype MTBDRplus, clinical
specimen

Klinik örneklerden tüberküloz tanısı ve hızlı rifampin ve izoniyazid direnci
saptanması için geno type MTBDRPlus testinin değerlendirilmesi
Amaç: Bu çalışmada Genotype MTBDRplus testinin klinik örneklerden tüberküloz tanısı ve hızlı rifampin (RIF) ve
izoniyazid (INH) saptanmasıdaki performansının belirlenmesi amaçlanmıştır.
Yöntem ve gereç: Aralık 2007 ve 2009 tarihleri arasında Ege Üniversitesi Tıp Fakültesi Tıbbi Mikrobiyoloji Anabilim
Dalı Mikobakteriyoloji Laboratuvarı’na rutin inceleme için gönderilen 57 hastaya ait toplam 90 klinik örnek (69
balgam örneği, 11 bronkoskopik aspirat, 5 bronkoalveoler lavaj, 4 derin trakeal aspirat, 1 lenf aspiratı) çalışmaya alındı.
Bulgular: Toplam 90 klinik örneğin 80’inde (% 88,9) MTDRplus testiyle geçerli sonuç elde edildi. Direkt bakısı pozitif
82 örneğin 74’ünde (% 90,2) MTDRplus ile geçerli sonuç alınırken, direkt bakısı negatif sekiz örneğin ikisinde geçersiz
sonuç alındı. MTBDRplus testiyle ilaç duyarlılık testi arasındaki genel uyumluluk oranı RİF direnci için % 97,5 (78/80)
ve INH direncini için % 98,8 (79/80) olarak sapatandı.
Sonuç: MTBDRplus klinik örneklerde ve kökenlerde RIF ve INH’a dirençli M. tuberculosis’in tanısında kullanılabilecek
yararlı bir araçtır. Buna karşın test sonuçları mutlaka kültür ve ilaç duyarlılık testleriyle doğrulanmalıdır.
Anahtar sözcükler: Mycobacterium tuberculosis, rifampin direnci, izoniyazid direnci, Genotype MTBDRplus, klinik
örnek
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Introduction
Mycobacterium tuberculosis remains one of the
most significant causes of death from an infectious
agent. The incidence of pulmonary tuberculosis in
Turkey is nearly 27.9 per 100,000 population (1).
The proportions of multidrug resistant tuberculosis
(MDR-TB) among new cases, previously treated
cases and all TB cases are 2.9%, 15.5%, and 4.9%,
respectively (1).
Collectively,
DNA
sequencing
studies
demonstrate that more than 95% of RIF-resistant M.
tuberculosis strains have a mutation within the 81-bp
hotspot region of the rpoB gene (2-4). In contrast,
the mutations causing INH resistance are located in
several regions (5). Approximately, 34.6% to 94.3%
of INH-resistant strains have been found to contain
mutations in codon 315 of the katG gene (6-10), 2.9%
to 21.5% contain mutations in the inhA promoter
region (6,7,9,10), and an additional 2% to 11.5% have
mutations in the ahpC-oxyR intergenic region (6,7,9).
Several molecular methods have been developed
in recent years for the diagnosis of tuberculosis and
rapid detection of drug resistance in clinical specimes,
including line probe assays (GenoType MTBDRplus;
Hain Lifescience GmbH, Nehren, Germany, INNO
LİPA Rif.TB; Innogenetics, Ghent, Belgium) and
real-time PCR (Xpert; Cepheid, Sunnyvale, CA,
USA). Molecular assays have been established to
allow the prediction of drug resistance in clinical
specimens within 1 working day and potentially are
the most rapid methods for the detection of drug
resistance (2,6,11-13). The Genotype MTBDR plus
assay (Hain Lifescience GmbH, Nehren, Germany)
is a novel kit-based method for the detection of the
most common mutations in the M. tuberculosis rpoB,
katG, and inhA genes (6,12).
The aim of the present study was to determine
the performance of the Genotype MTBDRplus assay
for diagnosis of tuberculosis and rapid detection of
rifampin and isoniazid resistance in smear-positive
clinical specimens. The results obtained by the
Genotype MTBDRplus assay were then compared
with the results obtained by culture and phenotypic
susceptibility testing.
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Materials and methods
Clinical specimens
A total of 90 clinical specimens of 57 patients
(69 sputum samples, 11 bronchoscopic aspirates, 5
bronchoalveolar lavage, 4 deep tracheal aspirate, 1
lymph aspirate) sent to the Ege University Medical
Faculty, Department of Medical Microbiology,
Mycobacteriology Laboratory between December
2007 and 2009 during the clinical routine were
included in the study. Clinical specimens were
processed by the conventional N-acetyl-Lcysteine–
NaOH method (14). After decontamination, smears
were prepared by the auramine-rhodamine acid-fast
staining method (14). Decontaminated specimens
were inoculated to Löwenstein-Jensen solid medium
and MB/BacT liquid medium (BioMérieux, Marcy
l’Etoile, France) for growth detection, the leftover
sediment of the decontaminated specimen was stored
at -20 °C. Smear positive specimens were studied in
2 weeks; smear negative specimens were studied after
growth of culture immediately.
Identification of Mycobacterium tuberculosis
complex (MTBC) strains from cultures and drug
susceptibility testing (DST)
After growth of the cultures, species identification
and, in cases in which MTBC strains were identified,
DST were performed. The identification of M.
tuberculosis from the grown cultures was confirmed
by the GenoType MTBDRplus assay.
The proportional method with 7H10 medium
had been used to test resistance to the INH and
RIF. Tests were performed with the standard critical
concentrations of INH (0.2 μg/mL) and RIF (1 μg/
mL).
Genotype MTBDRplus assay
The Genotype MTBDRplus assay was used
according to the instructions of the manufacturer.
Briefly, for DNA preparation, 1 mL of clinical specimen
was used. For PCR amplification, 35 μL of primernucleotide mix (provided with the kit), amplification
buffer containing 2.5 mM MgCl2, 1.25 U of FastStart
Taq polymerase (Roche Molecular Diagnostics,
Mannheim, Germany), and 5 μL of supernatant in a
final volume of 50 μL were used. The amplification
protocol consisted of 15 min of denaturation at 95
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wild-type probes. When the resistance to RIF or INH
was due to one of the 10 most frequently observed
mutations described above, a positive reaction was
obtained with at least one of the 10 mutant probes
and was always accompanied by a negative reaction
with the corresponding wild-type probe.

°C, followed by 10 cycles comprising 30 s at 95 °C and
120 s at 58 °C; an additional 35 cycles comprising 25
s at 95 °C, 40 s at 53 °C, and 40 s at 70 °C; and a final
extension at 70 °C for 8 min.
The MTBDRplus strip contains 27 probes,
including hybridization (CC) and amplification (AC)
controls. M. tuberculosis was detected in a sample by
the use of the M. tuberculosis complex-specific (TUB)
probe. The rpoB, katG, and inhA-specific regions
were detected by rpoB, katG, and inhA control probes,
respectively. The reactivities of an amplified fragment
with the 8 rpoB wild-type probes (rpoB WT1
through rpoB WT8), 2 inhA wild-type probes (inhA
WT1 and inhA WT2), and 1 katG wild-type probe
were used to detect the mutations that lead to RIF
and INH resistance in M. tuberculosis. Furthermore,
10 probes (mutant probes) were specifically designed
to hybridize the sequences of the 4 most frequently
observed rpoB, 4 inhA, and 2 katG mutations: rpoB
MUT1 (D516V), rpoB MUT2A (H526Y), rpoB
MUT2B (H526D), and rpoB MUT3 (S531L), inhA
MUT1 (-15C/T), inhA MUT2 (-16A/G), inhA MUT3
(-8T/C), and inhA MUT4(-8T/A), katG MUT1
(S315T1), and katG MUT2 (S315T2).

Results
A total of 90 clinical specimens, consisting of 82
smear-positive and 8 smear negative samples, were
included in the study. All clinical specimens tested
were culture positive for M. tuberculosis. Overall, 80
interpretable results were obtained for 90 specimens
(88.9%) by MTDRplus. There was no statistically
significant difference in readability rates between
clinical samples graded as 4+, 3+, and 2+ compared
to 1+ by logistic regression analaysis (P > 0.05).
While 74 of 82 (90.2%) smear positive specimens
gave interpretable results by MTDRplus, 2 of 8 smear
negative specimens gave invalid results (Table 1).
However the M. tuberculosis complex-specific (TUB)
control band was detected in 7 of 10 invalid results.
Interestingly 3 specimens, in which TUB control
band was negative, were smear-positive. As a result,
TUB control band was detected in 87 (96.7%) of 90
clinical specimens.

In conclusion, when all of the wild-type probes
gave a positive signal and all of the mutant probes
reacted negatively, the M. tuberculosis isolate was
considered susceptible to RIF and INH. When at
least one negative signal was obtained with the rpoB
wild-type probes, the isolate was considered resistant
to RIF, and same was true for the katG and inhA

Among the 80 interpretable clinical specimens,
obtained from 47 patients, 71 clinical specimens
obtained from 43 patients were pansusceptible, 5
clinical samples obtained from 2 patients had INHr

Table 1. MTBDRplus assay results according to the auramine-rhodamine microscopy staining for the culture positive 90 clinical
samples.
MTBDRplus

No. (%) of specimens

test result*

Smear 4+

Smear 3+

Smear 2+

Smear 1+

Smear negative

Total

MTBDRplus +

18 (85.7)

19 (100)

22 (88)

12 (70.6)

6 (75)

77 (85.6)

MTBDRplus ±

0 (0)

0 (0)

1(4)

2 (11.8)

0 (0)

3 ( 3.3)

MTBDRplus -

3 (14.3)

-

2(8)

3(17.6)

2 (25)

10 (11.1)

Total

21

19

25

17

8

90

* MTBDRplus + interpretable and concordant test results with DST, MTBDRplus ± interpretable and discordant test results with culture
and DST, MTBDRplus – invalid test results
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and RIFs pattern, 2 clinical samples obtained from
1 patient had INHr and RIFr pattern, and 2 clinical
samples obtained from 1 patient had INHs and RIFr
pattern (Table 2).
The overall rate of concordance between the results
of the MTBDRplus assay and those of the DST for the
assessment of RIF resistance was 97.5% (78/80; K =
0.655 ± 0.226 P < 0.001). The discordant 2 samples
were RIF susceptible with DST, but MTBDRplus
assays of these samples gave positive signals both
with rpoB MUT2B probe and WT rpoB probes. Both
samples were smear positive and obtained from the
same patient and their MTBDRplus assays made from
culture gave WT patterns (Table 3). The overall rate
of concordance between the 2 tests for assessment
of INH susceptibility was 98.8% (79/80; K = 0.926
± 0.073 P < 0.001). The discordant sample was INH
resistant according to the DST but INH susceptible
by MTBDRplus assay. The MTBDRplus assay of
this sample made from culture also gave katMUT1
pattern. The rate of concordance was also calculated

by taking into account only one sample per patient
(n = 47). The overall rate of concordance betwen
MTBDRplus and DST was 95.7 (45/47). The levels
of agreement was 97.9% (46/47; K = 0.657 ± 0.319
P < 0.001) for RIF and (46/47; K = 0.846 ± 0.151 P <
0.001) for INH.
Discussion
The MTBDRplus assay has been widely used in
clinical routine for identificatin of M. tuberculosis
complex and deteciton of RIF and INH resistance
from clinical strains. The MTBDRplus assay can also
be applied directly to clinical specimens. In several
studies performed recently, the rates of valid test
results for smear positive and smear negative clinical
specimes have been reported to be 91.7%-100% and
46.1%-76%, respectively (15-19). In concordance
with the result of Nikolayevsky et al. (15) but not
with that of Lacoma et al. (16), Hilleman et al. (17)
and Miotto et al. (18), our result with clinical samples

Table 2. Analysis of 9 RIF and/or INH resistant clinical samples obtained from 4 patients according to MTBDRplus assay.
Molecular DST
Sputum

Culture

Phenotypical DST

MTBDRplus patterns
ID

Smear results

RIF

INH

RIF

INH

RIF

INH 0.2

INH 1.0

J2368±

3+

MUT3

WT

MUT3

WT

R

S

S

J2433±

3+

MUT3

WT

MUT3

WT

R

S

S

K170*

1+

WT +MUT2B

katG MUT1

WT

katG MUT1

S

R

R

K171*

1+

WT +MUT2B

katG MUT1

WT

katG MUT1

S

R

R

K822

2+

WT

katG MUT1

WT

katG MUT1

S

R

R

K971¶

2+

WT

inhA MUT1

WT

inhA MUT1

S

R

S

K1019¶

2+

WT

inhA MUT1

WT

inhA MUT1

S

R

S

K1032¶

2+

WT

inhA MUT1

WT

inhA MUT1

S

R

S

K1059¶

1+

WT

inhA MUT1

WT

inhA MUT1

S

R

S

± J2368 and J2433 were obtained from same patients. *K170 and K171 were obtained from same patients.
¶ K971, K1019, K1032, and K1059 were obtained from same patients.
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Table 3. Analysis of disagreements between molecular (clinical specimens and cultures) and phenotypical DST results for the 80
interpretable clinical specimens.
Molecular DST
Clinical specimes

Culture

Phenotypical DST

MTBDRplus patterns
ID

Smear results

RIF

INH

RIF

INH

RIF

INH 0.2

INH 1.0

K1435

2+

WT

WT

WT

katG MUT1

S

R

R

K170*

1+

WT +MUT2B

katG MUT1

WT

katG MUT1

S

R

R

K171*

1+

WT +MUT2B

katG MUT1

WT

katG MUT1

S

R

R

*K170 and K171 were obtained from same patients

revealed 90.2% (74/82) valid test results for smearpositive specimens and 75% (6/8) for smear-negative
specimens. In contrast with Nikolayevskyy et al. (15)
we found that no statistically significant differences
in readability rates in clincal samples graded as 4+,
3+, and 2+ compared to 1+.
We found 3 kinds of invalid results in 10 of the
90 clinical specimens. For one smear positive sample
graded as 4+, all gene-specific hybridization bands
were absent, despite the presence of amplification
and the hybridization control bands (Figure, Strip 1).
When this sample was retested the same result was
obtained. Two postulates can be offered to explain
this situation. (i) The inhibitors in the specimen can
lead to inhibition of amplification of M. tuberculosis
genome in the specimen without any effect on the
amplification control in the primer-nucleotide
mix. (ii) Probably due to the nonhomogeneous
distrubition of bacilli in the specimen, there were no
bacilli in the PCR mix.
For 2 smear positive samples, there was an
absence of TUB band, despite the presence of some
gene-specific hybridization bands along the strip
(Figure, Strips 2 and 3). In the third kind of invalid
result, which was present in 7 cases (2 smear negative,
5 smear positive), the pattern of resistance was
incomplete because of the absence of some wild-type
probes or presence of mutation bands discordant
with wild-type probes (Figure, Strips 4 and 5).

CCACTUBrpoBrpoB WT1rpoB WT2rpoB WT3rpoB WT4rpoB WT5rpoB WT6rpoB WT7rpoB WT8rpoB MUT1rpoB MUT2ArpoB MUT2BrpoB MUT3katGkatG WTkatG MUT1katG MUT2inhAinhA WT1inhA WT2inhA MUT1inhA MUT2inhA MUT3AinhA MUT3BM1

2

3

4

5

Figure. Examples of invalid results obtained by MTBDRplus
assay. The positions of the oligonucleotides and the
control probes are given on the left.
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Of the 80 valid GenoType MTBDRplus assays,
3 clinical specimens obtained from 2 patients gave
discordant results with DST. However, the GenoType
MTBDRplus assay gave concordant test results
with DST in 90 clinical strains, in our study. One
smear positive clinical specimen graded as 2+ gave
susceptible pattern with GenoType MTBDRplus
assay, but GenoType MTBDRplus assay performed
from clinical strains of this sample had katG MUT1
pattern and INH resistance was detected by DST
(Table 3). Two specimens obtained from one patient,
GenoType MTBDRplus assay gave signal with both
rpoBWT probes and MUT2B probe despite the
presence of WT pattern with GenoType MTBDRplus
assay made from clinical strains and RIF resistance
was not detected by DST. It is well known that the
specimens tested can contain heteroresistant strains.

In case of heteroresistance, a mutated as well as
wild-type sequence can be detected in the respective
sample.
In conclusion, the test has a short turnaround
time and simultaneously provides the RIF and INH
susceptibility pattern in a working day. Although
the MTBDRplus assay could be a useful tool for
rapid identification of RIF- and INH-resistant M.
tuberculosis in both clinical samples and strains, the
test results must always be confirmed by culture and
DST.
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